 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| bempikibart (ADX-914) / Q32 Bio
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov) - Apr 21, 2025
P2, N=75, Recruiting, Sponsor: Q32 Bio Inc.
Active, not recruiting --> Recruiting | N=40 --> 75 | Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Dec 2024 --> Jun 2026
- bempikibart (ADX-914) / Q32 Bio
Initial Results From The SIGNAL-AA Study: Randomized Placebo Controlled Phase 2a Trial of a Bempikibart, Novel IL-7/TSLP Bifunctional Receptor Antagonist in Patients with Severe or Very Severe... (Chapin Theater - Level III) - Feb 21, 2025 - Abstract #AAD2025AAD_2160;
- || bempikibart (ADX-914) / Q32 Bio
Enrollment closed: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov) - Oct 3, 2024
P2, N=102, Active, not recruiting, Sponsor: Q32 Bio Inc.
Active, not recruiting --> Recruiting | N=40 --> 75 | Trial completion date: Dec 2024 --> Sep 2026 | Trial primary completion date: Dec 2024 --> Jun 2026 Recruiting --> Active, not recruiting
- | bempikibart (ADX-914) / Q32 Bio
Enrollment closed: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov) - May 10, 2024
P2, N=40, Active, not recruiting, Sponsor: Q32 Bio Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || bempikibart (ADX-914) / Q32 Bio
Trial completion date, Trial primary completion date: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov) - Feb 19, 2024
P2, N=102, Recruiting, Sponsor: Q32 Bio Inc.
Recruiting --> Active, not recruiting Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024
- | bempikibart (ADX-914) / Q32 Bio
Trial completion date, Trial primary completion date: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov) - Feb 19, 2024
P2, N=40, Recruiting, Sponsor: Q32 Bio Inc.
Trial completion date: May 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024 Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- | bempikibart (ADX-914) / Q32 Bio
Trial completion date, Trial primary completion date: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov) - Dec 31, 2023
P2, N=40, Recruiting, Sponsor: Q32 Bio Inc.
- bempikibart (ADX-914) / Q32 Bio
Phase classification: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov) - Nov 18, 2023
P2, N=40, Recruiting, Sponsor: Q32 Bio Inc.
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024 Phase classification: P2a --> P2
- | bempikibart (ADX-914) / Q32 Bio
Phase classification: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov) - Nov 18, 2023
P2, N=102, Recruiting, Sponsor: Q32 Bio Inc.
Phase classification: P2a --> P2 Phase classification: P2a --> P2
- || bempikibart (ADX-914) / Q32 Bio
Enrollment open: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov) - Sep 14, 2023
P2a, N=40, Recruiting, Sponsor: Q32 Bio Inc.
Phase classification: P2a --> P2 Not yet recruiting --> Recruiting
- || bempikibart (ADX-914) / Q32 Bio
New P2 trial, New P2a trial: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) (clinicaltrials.gov) - Aug 30, 2023
P2a, N=40, Not yet recruiting, Sponsor: Q32 Bio Inc.
- ||| bempikibart (ADX-914) / Q32 Bio
Enrollment open: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov) - Oct 13, 2022
P2a, N=110, Recruiting, Sponsor: Q32 Bio Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| bempikibart (ADX-914) / Q32 Bio
New P2a trial: Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) (clinicaltrials.gov) - Aug 19, 2022
P2a, N=110, Not yet recruiting, Sponsor: Q32 Bio Inc.
- || bempikibart (ADX-914) / Q32 Bio
Trial completion, Enrollment change: Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers (clinicaltrials.gov) - Jul 28, 2022
P1, N=42, Completed, Sponsor: Q32 Bio Inc.
Not yet recruiting --> Recruiting Recruiting --> Completed | N=72 --> 42
- ||| bempikibart (ADX-914) / Q32 Bio
Enrollment open: Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers (clinicaltrials.gov) - Sep 11, 2020
P1, N=72, Recruiting, Sponsor: Q32 Bio Inc.
Recruiting --> Completed | N=72 --> 42 Not yet recruiting --> Recruiting
- | bempikibart (ADX-914) / Q32 Bio
New P1 trial: Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers (clinicaltrials.gov) - Jul 23, 2020
P1, N=72, Not yet recruiting, Sponsor: Q32 Bio Inc.